
### [NCIT:C7917](http://purl.obolibrary.org/obo/NCIT_C7917)
**Label:** Stage II Cutaneous Melanoma AJCC v6 and v7

**Subclasses:** [NCIT:C8787](http://purl.obolibrary.org/obo/NCIT_C8787) (Stage II Lentigo Maligna Melanoma AJCC v6 and v7), [NCIT:C8791](http://purl.obolibrary.org/obo/NCIT_C8791) (Stage II Superficial Spreading Melanoma AJCC v6 and v7), 

**Class expressions from DL-Learner:**

- [UBERON:0002097](http://purl.obolibrary.org/obo/UBERON_0002097) (skin of body) 53.57%
- [NCIT:C90530](http://purl.obolibrary.org/obo/NCIT_C90530) (AJCC v7 Stage) 53.57%
- [NCIT:C90529](http://purl.obolibrary.org/obo/NCIT_C90529) (AJCC v6 Stage) 53.57%
- [NCIT:C43268](http://purl.obolibrary.org/obo/NCIT_C43268) (HMB-45-Positive Neoplastic Cells Present) 53.57%
- [NCIT:C40993](http://purl.obolibrary.org/obo/NCIT_C40993) (S-100-Positive Neoplastic Cells Present) 53.57%
- [NCIT:C40430](http://purl.obolibrary.org/obo/NCIT_C40430) (BRAF Gene Mutation) 53.57%
- [NCIT:C38620](http://purl.obolibrary.org/obo/NCIT_C38620) (Integumentary System Part) 53.57%
- [NCIT:C36156](http://purl.obolibrary.org/obo/NCIT_C36156) (Favorable Clinical Outcome) 53.57%
- [NCIT:C33563](http://purl.obolibrary.org/obo/NCIT_C33563) (Skin Tissue) 53.57%
- [NCIT:C28054](http://purl.obolibrary.org/obo/NCIT_C28054) (Stage II) 53.57%
- [NCIT:C13022](http://purl.obolibrary.org/obo/NCIT_C13022) (Skin Part) 53.57%
- [CL:0000148](http://purl.obolibrary.org/obo/CL_0000148) (melanocyte) 53.57%
- [CL:0000147](http://purl.obolibrary.org/obo/CL_0000147) (pigment cell) 53.57%
- [NCIT:C12471](http://purl.obolibrary.org/obo/NCIT_C12471) (Soft Tissue) and [UBERON:0000475](http://purl.obolibrary.org/obo/UBERON_0000475) (organism subdivision) 53.57%
- [NCIT:C12471](http://purl.obolibrary.org/obo/NCIT_C12471) (Soft Tissue) and [NCIT:C38620](http://purl.obolibrary.org/obo/NCIT_C38620) (Integumentary System Part) 53.57%


